FDA denies NDA for Dextenza

The FDA has sent a complete response letter to Ocular Therapeutix saying it cannot approve the Dextenza new drug application “in its present form,” according to a company press release.The letter did not raise any concerns regarding efficacy or safety of the clinical data in the NDA or request additional clinical trials for approval.